Results 111 to 120 of about 25,818 (186)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Lung Cancer: Targets and Therapy, 2016
Etienne Giroux Leprieur,1,2 Vincent Fallet,3,4 Jacques Cadranel,3,4 Marie Wislez3,4 1Respiratory Diseases and Thoracic Oncology Department, APHP-Ambroise Paré Hospital, Boulogne-Billancourt, France; 2EA4340 Laboratory, UVSQ, Paris-Saclay ...
Giroux Leprieur E, Fallet V, Cadranel J, Wislez M   +3 more
doaj  

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. [PDF]

, 2016
Antonio Araújo
core   +1 more source

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study [PDF]

, 2018
et al,, Gambacorti-Passerini, Carlo, Van Tine, Brian A   +2 more
core   +1 more source

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. [PDF]

Hematol Transfus Cell Ther
Avinery L, Regev D, Khamaisi H, Gopas J, Mahajna J.   +4 more
europepmc   +1 more source

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +1 more source

Crizotinib-induced hyperlipidemia in advanced lung adenocarcinoma: A case report and literature review. [PDF]

Medicine (Baltimore)
Ren S, Chen R.
europepmc   +1 more source

Evaluation of crizotinib as radiosensitizer in sacral chordoma cells: effects of combined carbon ion particle therapy. [PDF]

Med Oncol
Lohberger B, Glänzer D, Etschmaier V, Trajanoski S, Leithner A, Rinner B, Georg D.   +6 more
europepmc   +1 more source

Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis. [PDF]

iScience
Luo X, Du X, Chen Q, Wang C, Li L, He X, Gong Y, Chen J, Zhong X, Liu Y, Zhang X, Huang L.   +11 more
europepmc   +1 more source

Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. [PDF]

Front Oncol
Dong S, Jiang ZC, Gao L, Zhang R, Liu Y.
europepmc   +1 more source

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study. [PDF]

Transl Lung Cancer Res
Zhang H, Wu Z, Lu T, Zhang H, Li J, Zhang D, Yu S, Guo X, Feng X, Liu J, Shi Y, Gao X, Liu X, Chen M, Zhao J, Zhong W, Hu Y, Xu Y, Wang M.   +18 more
europepmc   +1 more source